{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:44:06Z","timestamp":1793781846899,"version":"4.6.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021316","name":"AstraZeneca Pharmaceuticals LP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.esmorw.2024.100060","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T14:42:53Z","timestamp":1721918573000},"page":"100060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Real-world treatment patterns and challenges of patients with biliary tract cancer: retrospective chart review survey in Europe (GARNET-2)"],"prefix":"10.1016","volume":"5","author":[{"given":"J.","family":"Bridgewater","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Szende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Paskow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Baur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.esmorw.2024.100060_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"issue":"10272","key":"10.1016\/j.esmorw.2024.100060_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmorw.2024.100060_bib3","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.esmorw.2024.100060_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.esmorw.2024.100060_bib6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.esmorw.2024.100060_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.esmorw.2024.100060_bib8","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling","volume":"35","author":"Bridgewater","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100060_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40880-017-0182-y","article-title":"The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection","volume":"36","author":"Kim","year":"2017","journal-title":"Chin J Cancer"},{"issue":"14","key":"10.1016\/j.esmorw.2024.100060_bib10","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.3390\/cancers13143507","article-title":"Real-world evidence on palliative gemcitabine and oxaliplatin (GemOx) combination chemotherapy in advanced biliary tract cancer","volume":"13","author":"Lagenfelt","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.esmorw.2024.100060_bib11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/medicina58111543","article-title":"Second-line chemotherapy in elderly patients with advanced biliary tract cancer: a multicenter real-world study","volume":"58","author":"Rizzo","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"10.1016\/j.esmorw.2024.100060_bib12","article-title":"Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer","volume":"4","author":"Thol","year":"2022","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100060_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11523-022-00942-6","article-title":"Optimizing patient pathways in advanced biliary tract cancers: recent advances and a French perspective","volume":"18","author":"Neuzillet","year":"2023","journal-title":"Target Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2024.100060_bib14","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.21037\/jgo-23-155","article-title":"Real-world treatment patterns and survival outcomes for treated biliary tract cancer patients using administrative databases in Ontario","volume":"14","author":"Seung","year":"2023","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.esmorw.2024.100060_bib15","series-title":"Biliary tract cancers: extrahepatic cholangiocarcinoma","year":"2013"},{"issue":"2","key":"10.1016\/j.esmorw.2024.100060_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"11s","key":"10.1016\/j.esmorw.2024.100060_bib17","doi-asserted-by":"crossref","first-page":"11S3","DOI":"10.1016\/S0007-4551(22)00463-5","article-title":"\u00c9tat des lieux des pratiques de prise en charge des cancers des voies biliaires en France: r\u00e9sultats de l\u2019enqu\u00eate nationale ACABi","volume":"109","author":"Delaye","year":"2022","journal-title":"Bull Cancer"},{"issue":"6","key":"10.1016\/j.esmorw.2024.100060_bib18","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/cam4.299","article-title":"Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review","volume":"3","author":"Fiteni","year":"2014","journal-title":"Cancer Med"},{"issue":"24","key":"10.1016\/j.esmorw.2024.100060_bib19","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.3748\/wjg.v29.i24.3825","article-title":"Regional variation in routes to diagnosis of cholangiocarcinoma in England from 2006 to 2017","volume":"29","author":"Zalin-Miller","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100060_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1470-2045(22)00746-X","article-title":"Inequalities in cancer prevention and care across Europe","volume":"24","author":"Berchet","year":"2023","journal-title":"Lancet Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmorw.2024.100060_bib21","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1016\/j.annonc.2022.07.084","article-title":"Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)","volume":"33","author":"Oh","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmorw.2024.100060_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113587","article-title":"Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: a joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies","volume":"200","author":"Parisi","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T22:39:53Z","timestamp":1729723193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820124000389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":21,"alternative-id":["S2949820124000389"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100060","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns and challenges of patients with biliary tract cancer: retrospective chart review survey in Europe (GARNET-2)","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100060"}}